You are here

NephCure Kidney International Announces Three New Scientific Advisory Board Members

KING OF PRUSSIA, Pa., March 8, 2019 /PRNewswire/ -- NephCure Kidney International (NephCure) is proud to announce the addition of three new members to its Scientific Advisory Board (SAB). Joining the distinguished SAB are Laura Barisoni, MD; Alessia Fornoni, MD, PhD; and Marva Moxey-Mims, MD.

"Our Scientific Advisory Board is made up of leading basic science and translational researchers, all of whom have made great strides in pushing glomerular disease research forward. We are thrilled to welcome Drs. Barisoni, Fornoni and Moxey-Mims to this esteemed group," Irving Smokler, PhD, Board President of NephCure announced.

NephCure's CEO, Joshua Tarnoff, added, "All three of our newest Scientific Advisory Board members bring diverse expertise and experiences that embody the spirit of our NephCure community. We are very fortunate to welcome them to our team, as 2019 is a pivotal year for clinical research and bringing forward new and effective treatments."

The chairman of NephCure's SAB, Martin Pollack, MD, also congratulated and welcomed the new members, "We are thrilled to welcome Drs. Fornoni, Barisoni, and Moxey-Mims to the Scientific Advisory Board.  All three are outstanding and dedicated physician-investigators who are committed to improving our ability to care for individuals with glomerular disease."

Laura Barisoni, MD is currently a Professor of Pathology and Medicine at Duke University Medical School. She is an accomplished diagnostic pathologist and an internationally recognized expert in the field of digital nephropathology and the use of digital image recognition as a diagnostic tool, particularly for glomerular diseases. Dr. Barisoni is the current President of the Renal Pathology Society, where she previously served for four years on the Board of Directors.

Actively involved in NIH-sponsored grants on podocytopathies and clinical trials on Nephrotic Syndrome and Fabry's disease, Dr. Barisoni also has remarkable teaching experience at numerous national and international courses in renal pathology.

Alessia Fornoni, MD, PhD is a tenured Professor of Medicine and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine. She is also the Chief of the Katz Family Division of Nephrology and Hypertension and serves as Director and Chair of the Peggy and Harold Katz Drug Discovery Center. Dr. Fornoni's lab was the first to report an important role of sphingolipids and cholesterol in the modulation of podocyte function in focal segmental glomerulosclerosis.

Her internationally recognized research findings, which are now being translated into humans with novel therapeutic applications, have challenged existing paradigms. Dr. Fornoni's vision is one that brings industry, investors and not-for-profit organizations around the table with the intent to match science with innovation and patients' motivation to find a cure for kidney diseases.

Marva Moxey-Mims, MD is a Professor of Pediatrics at the George Washington School of Medicine and the Chief of the Division of Nephrology at Children's National Health System in Washington, DC, where her focus is on clinical research to improve the care of children with kidney disease. She was most recently at the National Institute of Diabetes, and Digestive, and Kidney Diseases at the National Institutes of Health in Bethesda, MD, where she served as deputy director for clinical science in the Division of Kidney, Urologic and Hematologic Diseases.

Two of the studies Dr. Moxey-Mims initiated are the ongoing Chronic Kidney Disease in Children (CKiD) study, the largest study of pediatric chronic kidney disease ever conducted in North America, and the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial, the primary results of which were published in the New England Journal of Medicine.

NephCure Kidney International's Scientific Advisory Board includes:

NephCure Kidney International's mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases. Specifically, NephCure is focused on glomerular diseases such as: FSGS, IgA Nephropathy, Minimal Change Disease, Membranous Nephropathy, C3 Glomerulopathy, and Membranoproliferative Glomerulonephritis. NephCure is headquartered in King of Prussia, Pennsylvania. For more information about the organization, visit or call 1-866-637-4287.

Contact: Lauren Eva
Director, Marketing and Communications
610-540-0186 x21


Cision View original content to download multimedia:

SOURCE NephCure Kidney International